
Neyssa Marina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5839388/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chronic Health Conditions in Adult Survivors of Childhood Cancer. New England Journal of Medicine, 2006, 355, 1572-1582.	27.0	3,111
2	Health Status of Adult Long-term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. JAMA - Journal of the American Medical Association, 2003, 290, 1583-1592.	7.4	720
3	Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline. Journal of Clinical Oncology, 2004, 22, 4979-4990.	1.6	626
4	Biology and Therapeutic Advances for Pediatric Osteosarcoma. Oncologist, 2004, 9, 422-441.	3.7	604
5	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	2.8	354
6	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of Clinical Oncology, 2015, 33, 2279-2287.	1.6	329
7	Abnormalities of the Thyroid in Survivors of Hodgkin's Disease: Data from the Childhood Cancer Survivor Study ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3227-3232.	3.6	313
8	Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 2536-2541.	1.6	294
9	Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics, 2008, 121, e387-e396.	2.1	248
10	Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discovery, 2019, 9, 46-63.	9.4	245
11	Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. Journal of Clinical Oncology, 2004, 22, 2691-2700.	1.6	221
12	Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 2545-2551.	1.6	204
13	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	21.4	181
14	Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee. Pediatric Blood and Cancer, 2008, 51, 163-170.	1,5	164
15	Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multiâ€modality therapy: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2008, 51, 334-338.	1.5	164
16	Children's Oncology Group's 2013 blueprint for research: Bone tumors. Pediatric Blood and Cancer, 2013, 60, 1009-1015.	1.5	164
17	Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer, 2007, 110, 2385-2393.	4.1	161
18	Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: A report of the Pediatric Oncology Group and the Children's Cancer Group. American Journal of Obstetrics and Gynecology, 1999, 181, 353-358.	1.3	160

#	Article	IF	CITATIONS
19	A phase 2 trial of R1507, a monoclonal antibody to the insulinâ€like growth factorâ€l receptor (IGFâ€lR), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer, 2014, 120, 2448-2456.	4.1	158
20	Physical Performance Limitations in the Childhood Cancer Survivor Study Cohort. Journal of Clinical Oncology, 2009, 27, 2382-2389.	1.6	154
21	Outcome for adolescent and young adult patients with osteosarcoma. Cancer, 2012, 118, 4597-4605.	4.1	153
22	Treatment of Children and Adolescents With Stage II Testicular and Stages I and II Ovarian Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9048 and Children's Cancer Group 8891. Journal of Clinical Oncology, 2004, 22, 3563-3569.	1.6	152
23	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
24	Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 1989-1994.	1.6	138
25	Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clinical Cancer Research, 2003, 9, 5442-53.	7.0	135
26	Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. Cancer, 2015, 121, 467-475.	4.1	124
27	Changes in Children's Reports of Symptom Occurrence and Severity During a Course of Myelosuppressive Chemotherapy. Journal of Pediatric Oncology Nursing, 2010, 27, 307-315.	1.5	111
28	Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors. Journal of Clinical Oncology, 2007, 25, 3635-3643.	1.6	109
29	LONG-TERM SURVIVORS OF CHILDHOOD CANCER. Pediatric Clinics of North America, 1997, 44, 1021-1042.	1.8	105
30	Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. Cancer, 2005, 104, 841-847.	4.1	98
31	Twenty years of followâ€up of survivors of childhood osteosarcoma. Cancer, 2011, 117, 625-634.	4.1	91
32	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
33	A Genome-Wide Scan Identifies Variants in <i>NFIB</i> Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
34	Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1771-1779.	1.5	81
35	Prognostic Factors in Children With Extragonadal Malignant Germ Cell Tumors: A Pediatric Intergroup Study. Journal of Clinical Oncology, 2006, 24, 2544-2548.	1.6	76
36	Treatment of childhood germ cell tumors: Review of the St. Jude experience from 1979 to 1988. Cancer, 1992, 70, 2568-2575.	4.1	72

#	Article	IF	CITATIONS
37	Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group. Clinical Cancer Research, 2010, 16, 4024-4030.	7.0	72
38	Multiple Symptoms in Pediatric Oncology Patients: A Systematic Review. Journal of Pediatric Oncology Nursing, 2009, 26, 325-339.	1.5	71
39	Symptom Cluster Analyses Based on Symptom Occurrence and Severity Ratings Among Pediatric Oncology Patients During Myelosuppressive Chemotherapy. Cancer Nursing, 2012, 35, 19-28.	1.5	70
40	Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. European Journal of Cancer, 2013, 49, 2384-2391.	2.8	70
41	Phase II study of intermediateâ€dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2009, 52, 324-327.	1.5	67
42	Osteosarcoma: The Same Old Drugs or More?. Journal of Clinical Oncology, 2008, 26, 3102-3103.	1.6	62
43	Racial/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California, 1988-2011: A population-based observational study. Pediatric Blood and Cancer, 2015, 62, 1819-1825.	1.5	61
44	Angiogenesis and vascular targeting in Ewing sarcoma. Cancer, 2010, 116, 749-757.	4.1	58
45	The role of interferons in the treatment of osteosarcoma. Pediatric Blood and Cancer, 2010, 54, 350-354.	1.5	57
46	Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976. Cancer, 2008, 113, 2597-2604.	4.1	55
47	A pilot study of lowâ€dose antiâ€angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatric Blood and Cancer, 2013, 60, 409-414.	1.5	55
48	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology, 2020, 38, 2418-2426.	1.6	55
49	Primary malignancy of the salivary gland in children. Journal of Pediatric Surgery, 1994, 29, 44-47.	1.6	51
50	Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatric Blood and Cancer, 2016, 63, 47-53.	1.5	46
51	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. Journal of Clinical Oncology, 2021, 39, 4029-4038.	1.6	41
52	Use of HBA 71 and anti-β2-microglobulin to distinguish peripheral neuroepithelioma from neuroblastoma. Human Pathology, 1993, 24, 880-885.	2.0	39
53	Tumoral <i>TP53</i> and/or <i>CDKN2A</i> alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 759-765.	1.5	39
54	Local control in synchronous bilateral Wilms tumor. International Journal of Radiation Oncology Biology Physics, 1996, 36, 541-548.	0.8	38

#	Article	lF	CITATIONS
55	Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with wilms tumour. European Journal of Cancer, 2009, 45, 99-106.	2.8	38
56	An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy. Supportive Care in Cancer, 2011, 19, 353-361.	2.2	37
57	Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 57, 939-942.	1.5	36
58	Symptom Assessment in Pediatric Oncology. Cancer Nursing, 2014, 37, 252-262.	1.5	36
59	Changes in Health Status Among Aging Survivors of Pediatric Upper and Lower Extremity Sarcoma: A Report From the Childhood Cancer Survivor Study. Archives of Physical Medicine and Rehabilitation, 2013, 94, 1062-1073.	0.9	35
60	Application of the adult International Germ Cell Classification System to pediatric malignant nonâ€seminomatous germ cell tumors: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2008, 50, 746-751.	1.5	34
61	Complementary and alternative therapy use in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Pediatric Blood and Cancer, 2008, 50, 90-97.	1.5	31
62	Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells. Clinical Cancer Research, 2005, 11, 4561-4570.	7.0	30
63	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Âh: the Stanford Approach. Molecular Imaging and Biology, 2018, 20, 324-335.	2.6	29
64	Progress in the treatment of adolescents with acute lymphoblastic leukemia. Cancer, 1993, 71, 3400-3405.	4.1	24
65	HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatric Blood and Cancer, 2014, 61, 1558-1564.	1.5	23
66	Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 493-498.	1.5	23
67	Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b. Journal of Pediatrics, 1994, 125, 581-584.	1.8	20
68	Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report. Sarcoma, 2015, 2015, 1-8.	1.3	19
69	A summary of the osteosarcoma banking efforts: A report from the Children's Oncology Group and the QuadW Foundation. Pediatric Blood and Cancer, 2015, 62, 450-455.	1.5	19
70	Wilms?? Tumour. Drugs, 1998, 56, 597-605.	10.9	18
71	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. Sarcoma, 2020, 2020, 1-6.	1.3	17
72	Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul) Journal of Clinical Oncology, 2016, 34, 11001-11001.	1.6	17

#	Article	IF	CITATIONS
73	Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG). Pediatric Blood and Cancer, 2013, 60, 1602-1605.	1.5	16
74	A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors. Cancer, 1993, 71, 3661-3665.	4.1	15
75	Peritoneal metastases in children with cancer. , 1998, 83, 385-390.		14
76	MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response―randomization Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	14
77	High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission. Journal of Clinical Oncology, 2005, 23, 4262-4264.	1.6	13
78	Predictors of acute chemotherapyâ€associated toxicity in patients with Ewing sarcoma. Pediatric Blood and Cancer, 2012, 59, 611-616.	1.5	13
79	Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria. American Journal of Clinical Pathology, 2013, 139, 818-825.	0.7	13
80	Lack of heritability in ovarian germ cell malignancies. American Journal of Obstetrics and Gynecology, 1994, 170, 1803-1808.	1.3	12
81	Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experience. , 1996, 27, 145-148.		12
82	Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors Journal of Clinical Oncology, 2019, 37, 2529-2529.	1.6	12
83	Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. Journal of Surgical Oncology, 2016, 113, 351-354.	1.7	10
84	Osteosarcoma-Approach to Therapy. Pediatric Oncology, 2021, , 91-109.	0.5	10
85	Highâ€intensity focused ultrasound (HIFU) is not indicated for treatment of primary bone sarcomas. Cancer, 2011, 117, 2822-2822.	4.1	9
86	Congenital peribronchial myofibroblastic tumor: case report of an asymptomatic infant with a rapidly enlarging pulmonary mass and review of the literature. Annals of Clinical and Laboratory Science, 2015, 45, 83-9.	0.2	9
87	Phase I trial of subcutaneous interleukin-1α in children with malignant solid tumors. , 1997, 28, 444-450.		8
88	Comparison of latino and non-Latino patients with Ewing sarcoma. Pediatric Blood and Cancer, 2014, 61, 233-237.	1.5	8
89	Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient. Pediatrics, 2015, 136, e1377-e1381.	2.1	8
90	A phase I study of sulofenur in refractory pediatric malignant solid tumors. Investigational New Drugs, 1995, 13, 63-66.	2.6	7

#	Article	IF	CITATIONS
91	Nongestational Choriocarcinoma in the Postpartum Period. Journal of Pediatric Hematology/Oncology, 1998, 20, 169-173.	0.6	7
92	Comparison of Cytokines in Children with Recurrent Solid Tumors Treated with Intensive Chemotherapy. Journal of Pediatric Hematology/Oncology, 1998, 20, 62-68.	0.6	7
93	Knowledge of hepatitis C virus screening in longâ€ŧerm pediatric cancer survivors. Cancer, 2010, 116, 974-982.	4.1	7
94	Immune approaches to treating osteosarcoma. Cancer Biology and Therapy, 2009, 8, 981-983.	3.4	6
95	The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS) Journal of Clinical Oncology, 2012, 30, 9503-9503.	1.6	6
96	Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A populationâ€based study. Pediatric Blood and Cancer, 2021, 68, e28998.	1.5	4
97	MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization Journal of Clinical Oncology, 2013, 31, LBA10504-LBA10504.	1.6	4
98	Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. JMIR Research Protocols, 2019, 8, e14406.	1.0	4
99	Response to "imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee― Pediatric Blood and Cancer, 2008, 51, 839-840.	1.5	3
100	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma Journal of Clinical Oncology, 2012, 30, 10081-10081.	1.6	3
101	Anti-insulin growth factor receptor therapy in Ewing sarcoma. F1000 Medicine Reports, 2009, 1, .	2.9	3
102	Maximum tumor dimension and tumor volume as prognostic factors in patients with newly diagnosed localized Ewing sarcoma (ES)- a report from the Children's Oncology Group (COG) Journal of Clinical Oncology, 2020, 38, 11529-11529.	1.6	3
103	Cytomegalovirus causing pericarditis with tamponade in an adolescent with cancer. , 1996, 26, 70-70.		2
104	Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. Cancer Chemotherapy and Pharmacology, 1997, 41, 229-236.	2.3	1
105	Treating pediatric osteosarcoma: recent clinical trial evidence. Clinical Investigation, 2013, 3, 967-978.	0.0	1
106	Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children's Oncology Group Journal of Clinical Oncology, 2012, 30, 9537-9537.	1.6	1
107	A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung Journal of Clinical Oncology, 2013, 31, TPS10591-TPS10591.	1.6	1
108	Mortality in young adults with Ewing sarcoma treated at specialized cancer centers in California Journal of Clinical Oncology, 2017, 35, 10538-10538.	1.6	1

#	Article	IF	CITATIONS
109	Reply to Second malignancies in Ewing sarcoma survivors. Cancer, 2017, 123, 4075-4076.	4.1	0
110	Abstract 4593: Genome-wide association study identifies novel loci associated with osteosarcoma , 2013, , .		0
111	Utilization of subspecialty care by Hispanic pediatric oncology patients, California 1983-2010 Journal of Clinical Oncology, 2013, 31, e17504-e17504.	1.6	0
112	Discordance of oncologic surgical classifications in COG studies Journal of Clinical Oncology, 2013, 31, 10528-10528.	1.6	0
113	Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body Journal of Clinical Oncology, 2017, 35, 10519-10519.	1.6	0
114	Abstract PR05: Genomic analysis of osteosarcoma reveals opportunities for targeted therapy. , 2018, , .		0